Rosetta to Debut Array-Based Cancer-of-Unknown-Primary Test in H2
March 23, 2010
Rosetta to Debut Array-Based Cancer-of-Unknown-Primary Test in H2
CEO Kenneth Berlin said that the next-generation version of Rosetta's miRview Mets test will run on an array platform, and that the firm's CLIA lab was recently upgraded to include a microarray room to process the test.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Rosetta Genomics to Intensify Marketing Outreach for Menu of miRview Microarray Tests
April 2, 2013 / BioArray News - Rosetta Genomics' 2012 Revenues Nearly Double
March 25, 2013 / GenomeWeb Daily News - New York State Clears Rosetta Genomics' Array-based Cancer of Unknown Primary Test
December 13, 2011 / BioArray News - Rosetta Gets NY State Approval for Tumor Test
December 9, 2011 / GenomeWeb Daily News - With Second-Gen Test Menu in Place, Rosetta Genomics Sets Sights on Third-Gen Pipeline
September 16, 2010 / Gene Silencing News